A new research paper was published in Volume 12 of Oncoscience on October 14, 2025, titled "Bridging clinical insight and laboratory model in high-grade serous ovarian carcinoma (HGSOC) using DNA ...
Researchers say that in the course of developing a new model for ovarian cancer, they've developed additional evidence that serous uterine cancer possibly begins in the fallopian tubes, not the uterus ...
Most uterine cancers have excellent five-year survival rates—up to 95% for localized cancer. Serous uterine cancer is an exception, with five-year survival rates of 35% to 50% for stage 1 or 2 cancer.
Figure 1: Hemocytometer dead cells count. Here is the bar graph showing the hemocytometer based dead cell counts for each treatment group across day 1, day 2 and day 4 (24 hours post treatment). The ...
Homologous recombination deficiency (HRD) status and response to platinum-based chemotherapy and PARP inhibitors in Chinese patients with ovarian cancer.
Figure 1: Hemocytometer dead cells count. Here is the bar graph showing the hemocytometer based dead cell counts for each treatment group across day 1, day 2 and day 4 (24 hours post treatment). The ...
New research yields a novel method to use ultrasound to enhance machine learning's ability to accurately diagnose -- or rule out -- ovarian cancer. Although ovarian cancer is the deadliest type of ...
Although ovarian cancer is the deadliest type of cancer for women, only about 20% of cases are found at an early stage, as there are no real screening tests for them and few symptoms to prompt them.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results